Belgian Market Community

KBC’s value looks very different depending on whether you focus on the cash it plans to return to shareholders or the strength of its balance sheet. The big question is whether today’s generous payouts can hold up if the bank’s risk profile and loan losses move back toward more typical levels.Read more

SIPEF is riding a lift in palm oil and banana output while benefiting from stronger demand tied to biofuels, and it’s backing that up with a solid cash position and investments in cleaner operations. The big watch‑outs are political and trade shocks, tricky weather, and rising costs that could squeeze results if conditions turn.Read more

Proximus stops being a “safe income” stock after cutting its payout, but the case now shifts to a long rebuilding story built on fiber and nationwide networks with government backing. The big question is whether today’s pain in its global messaging business and heavy spending phase sets up a stronger cash engine later—or drags on longer than expected.Read more

Agfa-Gevaert is trying to turn itself from a fading film business into a focused company built around hospital imaging software, industrial printers, and new materials used in clean-energy equipment. The upside comes from newer products gaining traction, but the company still has to manage old liabilities and the slow decline of its legacy film activities.Read more

EU#8 - Anheuser-Busch InBev: Courage, Capital, and the Discipline to Build an Empire It takes only three ingredients to brew beer: water, barley, and hops. But building a global beer empire is different.Read more

NAV As Sofina is an investment holding company, NAV is an important factor in my evaluation. This Net Asset Value is estimated at a price share of 297 Eur, up from 294 last year.Read more

Most investors still treat D’Ieteren like a traditional Belgian car business, but the real value may sit in its fast-growing glass-repair leader Belron and other mobility services. If those stronger businesses keep delivering while the weak car unit stays contained, the market’s “holding company discount” could finally start to fade.Read more

argenx is betting that its lead drug VYVGART can move beyond one rare disease and become a platform treatment across several autoimmune conditions. The upside comes from a steady stream of upcoming study results and new uses, but the story can also break if trials disappoint or drug-pricing pressure intensifies.Read more

Kinepolis looks like it’s moving from a shaky cinema rebound to a more solid comeback, helped by stronger movie lineups and its recent U.S. acquisition. But the story still hinges on whether ticket demand holds up and integration goes smoothly, making the upside and downside both easy to imagine.Read more